OKYO Pharma Limited
OKYO
$-0.04
Change (1 day)
$2.12
Year High
$0.81
Year Low
Categories
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
P/B ratio for OKYO Pharma Limited (OKYO)
P/B ratio as of 2024: -7.34
According to OKYO Pharma Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -7.34. At the end of 2023 the company had a P/B ratio of -18.21.
P/B ratio history for OKYO Pharma Limited from 2008 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | -7.34 |
| 2023 | -18.21 |
| 2022 | 1202.67 |
| 2021 | 332.21 |
| 2020 | -12400.27 |
| 2019 | 4278.08 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 30.01 |
| 2015 | 27.15 |
| 2014 | 13.92 |
| 2013 | 14.98 |
| 2012 | 14.15 |
| 2011 | 50.03 |
| 2010 | 14.58 |
| 2009 | 21.62 |
| 2008 | 3.70 |